Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.32 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806931 | 1.00 | G6PD (0.47) | G6PDABL1RIN1CYP19A1GPBAR1 | |
| SCHEMBL6802275 | 0.85 | ABL1 (0.44) | G6PDABL1RIN1CYP19A1GPBAR1 | |
| SCHEMBL6802281 | 0.85 | ABL1 (0.44) | G6PDABL1RIN1CYP19A1GPBAR1 | |
| SCHEMBL7185765 | 0.82 | G6PD (0.67) | G6PDABL1RIN1GPBAR1AKR1B10 | |
| SCHEMBL7185770 | 0.82 | G6PD (0.67) | G6PDABL1RIN1GPBAR1AKR1B10 | |
| SCHEMBL7192083 | 0.82 | G6PD (0.67) | G6PDABL1RIN1GPBAR1AKR1B10 | |
| SCHEMBL8528354 | 0.79 | G6PD (0.69) | G6PDCYP19A1GPBAR1 | |
| SCHEMBL8640096 | 0.79 | G6PD (0.69) | G6PDCYP19A1GPBAR1 | |
| SCHEMBL9764804 | 0.79 | G6PD (0.69) | G6PDCYP19A1GPBAR1 | |
| SCHEMBL5961150 | 0.79 | G6PD (0.69) | G6PDCYP19A1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | HSD3B1, IL4, HSD17B7 | G6PD 526/4885ABL1 2656/4885RIN1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.